Brokerages forecast that Vericel Corp (NASDAQ:VCEL) will post sales of $22.61 million for the current quarter, Zacks reports. Two analysts have provided estimates for Vericel’s earnings. The highest sales estimate is $22.71 million and the lowest is $22.50 million. Vericel posted sales of $18.03 million in the same quarter last year, which suggests a positive year-over-year growth rate of 25.4%. The firm is scheduled to issue its next earnings report on Tuesday, May 14th.
On average, analysts expect that Vericel will report full-year sales of $112.44 million for the current financial year, with estimates ranging from $112.28 million to $112.60 million. For the next fiscal year, analysts anticipate that the company will post sales of $138.07 million, with estimates ranging from $134.64 million to $141.50 million. Zacks’ sales calculations are an average based on a survey of sell-side analysts that cover Vericel.
Vericel (NASDAQ:VCEL) last announced its quarterly earnings results on Tuesday, February 26th. The biotechnology company reported $0.11 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.05 by $0.06. The firm had revenue of $31.34 million during the quarter, compared to analyst estimates of $28.69 million. Vericel had a negative return on equity of 7.58% and a negative net margin of 8.96%. Vericel’s quarterly revenue was up 34.2% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.01 earnings per share.
A number of analysts recently issued reports on the company. BidaskClub upgraded Vericel from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Investment Research upgraded Vericel from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Tuesday, March 5th. Needham & Company LLC lowered Vericel from a “buy” rating to a “hold” rating and set a $17.92 price target for the company. in a report on Thursday, February 28th. Finally, Oppenheimer assumed coverage on Vericel in a report on Tuesday, January 29th. They issued an “outperform” rating and a $23.00 price target for the company. Three equities research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the stock. Vericel has an average rating of “Buy” and a consensus target price of $20.73.
Shares of NASDAQ VCEL traded down $0.17 during trading hours on Friday, reaching $18.50. The stock had a trading volume of 519,652 shares, compared to its average volume of 652,117. The firm has a market capitalization of $817.06 million, a price-to-earnings ratio of -131.64 and a beta of 3.02. Vericel has a 52-week low of $8.95 and a 52-week high of $21.00.
In related news, Director Steven C. Gilman sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, February 28th. The shares were sold at an average price of $18.02, for a total value of $135,150.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Gerard J. Michel sold 10,000 shares of the business’s stock in a transaction that occurred on Monday, February 11th. The stock was sold at an average price of $17.09, for a total transaction of $170,900.00. The disclosure for this sale can be found here. Insiders sold 43,125 shares of company stock valued at $781,875 in the last three months. 4.50% of the stock is currently owned by insiders.
A number of large investors have recently modified their holdings of the stock. Virtu Financial LLC bought a new position in Vericel in the first quarter worth approximately $298,000. Deutsche Bank AG increased its position in shares of Vericel by 151.1% during the fourth quarter. Deutsche Bank AG now owns 237,992 shares of the biotechnology company’s stock worth $4,140,000 after purchasing an additional 143,220 shares in the last quarter. American Century Companies Inc. acquired a new position in shares of Vericel during the fourth quarter worth $2,275,000. Geode Capital Management LLC increased its position in shares of Vericel by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 496,490 shares of the biotechnology company’s stock worth $8,638,000 after purchasing an additional 21,962 shares in the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new position in shares of Vericel during the fourth quarter worth $2,497,000. 83.30% of the stock is owned by institutional investors.
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns.
Further Reading: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.